These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34455369)

  • 1. Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
    Kondo N; Nagano Y; Hasegawa A; Ishizawa M; Katagiri K; Yoneda T; Masuda T; Kannagi M
    Biochem Biophys Res Commun; 2021 Oct; 574():104-109. PubMed ID: 34455369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
    Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2.
    Song Z; Wu W; Chen M; Cheng W; Yu J; Fang J; Xu L; Yasunaga JI; Matsuoka M; Zhao T
    J Virol; 2018 Dec; 92(24):. PubMed ID: 30258009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
    Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
    Clin Cancer Res; 2024 Jul; 30(14):3023-3035. PubMed ID: 38723281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID2 is a pomalidomide-dependent CRL4
    Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
    Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
    Zhu YX; Kortuem KM; Stewart AK
    Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peridinin, a carotenoid, inhibits proliferation and survival of HTLV-1-infected T-cell lines.
    Ishikawa C; Jomori T; Tanaka J; Senba M; Mori N
    Int J Oncol; 2016 Oct; 49(4):1713-21. PubMed ID: 27499015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.
    Rauch DA; Olson SL; Harding JC; Sundaramoorthi H; Kim Y; Zhou T; MacLeod AR; Challen G; Ratner L
    Retrovirology; 2020 Aug; 17(1):27. PubMed ID: 32859220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
    Gandhi AK; Mendy D; Waldman M; Chen G; Rychak E; Miller K; Gaidarova S; Ren Y; Wang M; Breider M; Carmel G; Mahmoudi A; Jackson P; Abbasian M; Cathers BE; Schafer PH; Daniel TO; Lopez-Girona A; Thakurta A; Chopra R
    Br J Haematol; 2014 Jan; 164(2):233-44. PubMed ID: 24206017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
    Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
    Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
    Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
    Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
    BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
    Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
    Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells
    Wang Y; Shimosaki S; Ikebe E; Iha H; Yamamoto JI; Fife N; Ichikawa T; Hori M; Ogata M; Tsukamoto Y; Hijiya N; Moriyama M; Hagiwara S; Kusano S; Saito M; Ahmed K; Nishizono A; Handa H; Morishita K
    Front Oncol; 2023; 13():1272528. PubMed ID: 38344143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
    Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
    Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.